Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268020 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
A Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01268020: Completed Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
NCT01268020 is a Early Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01268020, a Early Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess \[18F\]-FMH3 PET imaging as a tool to evaluate the activity of the H3 receptor in the brain of Alzheimer Disease (AD) research participants
Primary Outcome
To assess the dynamic uptake and washout of \[18F\]-FMH3, an imaging marker targeting the histamine H3 receptor in brain, using positron emission tomography (PET) in subjects with Alzheimer (AD) and healthy controls (HC).
Interventions
- DRUG [18F]-FMH3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Early Phase 1 |
What the finished NCT01268020 record still lists
NCT01268020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]-FMH3 is the first listed.
NCT01268020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01268020 about?
NCT01268020 is a clinical study titled "Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC". The underlying goal of this study is to assess \[18F\]-FMH3 PET imaging as a tool to evaluate the activity of the H3 receptor in the brain of Alzheimer Disease (AD) research participants
What is the current status of trial NCT01268020?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01268020?
The interventions under investigation include: [18F]-FMH3 (DRUG).
Who is sponsoring clinical trial NCT01268020?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01268020's enrollment target sits among peer trials
5 1888th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia